Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Important safety information on synchromed ii and synchromed el infusion pumps to healthcare professionals regarding the following: 1.Pump refill procedure safety update: update to the of january 18 2011 medical device safety alert letter titled "important clinical information about pocket fills" 2.Synchromedr implantable infusion pump internal shorting: provide safety information and patient management recommendations related the potential for electrical shorting internal to the synchromed infusion pump. 3.Synchromedr implantable infusion pump priming bolus: important safety information and patient management recommendations regarding the unintended delivery of drug during the priming bolus function for the synchromedr implantable infusion pump.
Model Catalog: 8627-18 (Lot serial: All lots contact mfg); Model Catalog: 8627-10 (Lot serial: All lots contact mfg); Model Catalog: 8626L10 (Lot serial: All lots contact mfg); Model Catalog: 8626-18 (Lot serial: All lots contact mfg); Model Catalog: 8626-10 (Lot serial: All lots contact mfg); Model Catalog: 8627L10 (Lot serial: All lots contact mfg); Model Catalog: 8627L18 (Lot serial: All lots contact mfg); Model Catalog: 8626L18 (Lot serial: All lots contact mfg); Model Catalog: 8637 (Lot serial: All lots contact mfg)
“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.